Journal article
Risk and response adapted therapy for early stage Hodgkin lymphoma: A prospective multicenter study of the Australasian Leukaemia and lymphoma group/trans-tasman radiation oncology group
A Wirth, A Grigg, M Wolf, D Goldstein, C Johnson, S Davis, G Dutu, P Kypreos, C Smith, A Kneebone, M Herzberg, D Joseph, J Catalano, D Roos, J Stone, J Reynolds
Leukemia and Lymphoma | TAYLOR & FRANCIS LTD | Published : 2011
Abstract
In this prospective, multicenter, non-randomized study for patients with stage I-II Hodgkin lymphoma, group 1 (without risk-factors [RF]) had three cycles of ABVD chemotherapy (adriamycin, bleomycin, vinblastine, and dacarbazine) and group 2 (any of bulk, extranodal site, >3 regions, raised erythrocyte sedimentation rate [ESR]) and group 3 (B-symptoms) received four cycles. Involved field radiotherapy (IFRT) 30 Gy was given after adequate chemotherapy response. Five-year overall survival and freedom from progression (FFP) were 96% (95% confidence interval [CI] 91-98%) and 90% (84-94%), respectively. Five-year FFP was 97% (90-99%), 89% (75-95%), and 73% (52-86%) for groups 1, 2, and 3, respec..
View full abstractGrants
Funding Acknowledgements
This work was supported by Amgen Australia.